{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:09:47Z","timestamp":1791994187972,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017481","name":"Ulusal Metroloji Enstit\u00fcs\u00fc, T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","award":["222S038"],"award-info":[{"award-number":["222S038"]}],"id":[{"id":"10.13039\/501100017481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This study aims to investigate the effects of a low-advanced glycation end products(AGEs) diet versus a standard AGE-containing weight-loss diet on metabolic and hormonal profiles of overweight phenotype-A polycystic ovary syndrome(PCOS) patients.A randomized controlled interventional study.A total of 44 Rotterdam phenotype-A PCOS patients aged 19\u201335 were enrolled between January 2022 and May 2023. They were randomly assigned to 12-weeks of an energy-restricted Standard-AGEs diet(S-AGEs) or an energy-restricted Low-AGEs diet(L-AGEs). At baseline and after 12-weeks of intervention, weight loss, oligo-amenorrhea, hormonal profiles, plasma lipid profiles, and inflammation markers were evaluated. During the intervention, 8 participants from the L-AGEs group and 6 from the S-AGEs group dropped out. Completers had similar baseline characteristics to dropouts. In the per-protocol analysis, similar weight loss was observed in the L-AGEs(n\u2009=\u200914) and S-AGEs(n\u2009=\u200916) groups compared to baseline weight [-8.4 [-10.3 to -5.8] vs. -5.2 [-8.8 to -4.6] kg, respectively, p\u2009=\u20090.183]. However, in the L-AGEs group, fasting glucose levels decreased significantly more compared to the S-AGEs group (-8.5 [-11.5 to -3.5] vs. -0.5 [-3.7 to 0.7] mmol\/L, respectively, p\u2009=\u20090.027). Following the diet intervention in the L-AGEs group, the waist-to-hip circumference ratio, LDL-cholesterol, TNF-\u03b1, total testosterone (TT), free-androgen index (FAI), and anti-M\u00fcllerian hormone (AMH) levels significantly decreased compared to baseline levels, while sex hormone-binding globulin (SHBG) levels increased. In contrast, there was no statistically significant change in these parameters in the S-AGEs group.In addition to weight-loss, reducing dietary AGEs intake resulted in significantly greater improvements in metabolic and hormonal profiles among phenotype-A PCOS patients. Clinicaltrials.gov registration no. NCT05830487.<\/jats:p>","DOI":"10.1007\/s43032-025-01808-8","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T19:17:27Z","timestamp":1739560647000},"page":"1190-1201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Metabolic and Hormonal Profiles between Low-Advanced Glycation End Products (AGEs) and Standard AGEs-Containing Weight-Loss Diets in Overweight Phenotype-A PCOS Patients: A Randomized Clinical Trial"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-9154","authenticated-orcid":false,"given":"Merve","family":"Ozdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7000-7580","authenticated-orcid":false,"given":"Sezcan","family":"Mumusoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8177-0300","authenticated-orcid":false,"given":"Pelin","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"2","key":"1808_CR1","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1093\/ejendo\/lvad096","volume":"189","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43-g64. https:\/\/doi.org\/10.1093\/ejendo\/lvad096.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1808_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/ijms23020583","volume":"23","author":"HM Sadeghi","year":"2022","unstructured":"Sadeghi HM, et al. Polycystic ovary syndrome: A comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci. 2022;23(2):583. https:\/\/doi.org\/10.3390\/ijms23020583.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1808_CR3","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/humrep\/dey256","volume":"33","author":"HJ Teede","year":"2018","unstructured":"Teede HJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602\u201318. https:\/\/doi.org\/10.1093\/humrep\/dey256.","journal-title":"Hum Reprod"},{"key":"1808_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coemr.2020.03.004","volume":"12","author":"S Mumusoglu","year":"2020","unstructured":"Mumusoglu S, Yildiz BO. Polycystic ovary syndrome phenotypes and prevalence: Differential impact of diagnostic criteria and clinical versus unselected population. Current Opinion in Endocrine and Metabolic Research. 2020;12:66\u201371. https:\/\/doi.org\/10.1016\/j.coemr.2020.03.004.","journal-title":"Current Opinion in Endocrine and Metabolic Research"},{"issue":"17","key":"1808_CR5","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.3390\/nu14173578","volume":"14","author":"M Mouanness","year":"2022","unstructured":"Mouanness M, et al. Contribution of advanced glycation end products to PCOS key elements: A narrative review. Nutrients. 2022;14(17):3578. https:\/\/doi.org\/10.3390\/nu14173578.","journal-title":"Nutrients"},{"issue":"3","key":"1808_CR6","doi-asserted-by":"publisher","first-page":"Cd007506","DOI":"10.1002\/14651858.CD007506.pub4","volume":"3","author":"SS Lim","year":"2019","unstructured":"Lim SS, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;3(3):Cd007506. https:\/\/doi.org\/10.1002\/14651858.CD007506.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1808_CR7","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1210\/clinem\/dgab232","volume":"106","author":"BH Al Wattar","year":"2021","unstructured":"Al Wattar BH, et al. Clinical practice guidelines on the diagnosis and management of polycystic ovary syndrome: a systematic review and quality assessment study. J Clin Endocrinol Metab. 2021;106(8):2436\u201346. https:\/\/doi.org\/10.1210\/clinem\/dgab232.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1808_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tem.2019.01.005","volume":"30","author":"Z Merhi","year":"2019","unstructured":"Merhi Z, Kandaraki EA, Diamanti-Kandarakis E. Implications and Future Perspectives of AGEs in PCOS Pathophysiology. Trends Endocrinol Metab. 2019;30(3):150\u201362. https:\/\/doi.org\/10.1016\/j.tem.2019.01.005.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"1808_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2265.2004.02170.x","volume":"62","author":"E Diamanti-Kandarakis","year":"2005","unstructured":"Diamanti-Kandarakis E, et al. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2005;62(1):37\u201343. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02170.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1808_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2265.2008.03247.x","volume":"69","author":"E Diamanti-Kandarakis","year":"2008","unstructured":"Diamanti-Kandarakis E, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2008;69(4):634\u201341. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03247.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"1808_CR11","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.3390\/nu7125524","volume":"7","author":"D Garg","year":"2015","unstructured":"Garg D, Merhi Z. Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS? Nutrients. 2015;7(12):10129\u201344. https:\/\/doi.org\/10.3390\/nu7125524.","journal-title":"Nutrients"},{"issue":"1","key":"1808_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/humrep\/det383","volume":"29","author":"Z Merhi","year":"2014","unstructured":"Merhi Z. Advanced glycation end products and their relevance in female reproduction. Hum Reprod. 2014;29(1):135\u201345. https:\/\/doi.org\/10.1093\/humrep\/det383.","journal-title":"Hum Reprod"},{"key":"1808_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.fct.2013.06.052","volume":"60","author":"MW Poulsen","year":"2013","unstructured":"Poulsen MW, et al. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol. 2013;60:10\u201337. https:\/\/doi.org\/10.1016\/j.fct.2013.06.052.","journal-title":"Food Chem Toxicol"},{"issue":"12","key":"1808_CR14","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1073\/pnas.94.12.6474","volume":"94","author":"T Koschinsky","year":"1997","unstructured":"Koschinsky T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94(12):6474\u20139. https:\/\/doi.org\/10.1073\/pnas.94.12.6474.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1808_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jada.2010.03.018","volume":"110","author":"J Uribarri","year":"2010","unstructured":"Uribarri J, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911-16.e12. https:\/\/doi.org\/10.1016\/j.jada.2010.03.018.","journal-title":"J Am Diet Assoc"},{"issue":"5","key":"1808_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1161\/01.RES.84.5.489","volume":"84","author":"AM Schmidt","year":"1999","unstructured":"Schmidt AM, et al. Activation of Receptor for Advanced Glycation End Products. Circ Res. 1999;84(5):489\u201397. https:\/\/doi.org\/10.1161\/01.RES.84.5.489.","journal-title":"Circ Res"},{"issue":"8","key":"1808_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jada.2004.05.214","volume":"104","author":"T Goldberg","year":"2004","unstructured":"Goldberg T, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104(8):1287\u201391. https:\/\/doi.org\/10.1016\/j.jada.2004.05.214.","journal-title":"J Am Diet Assoc"},{"issue":"12","key":"1808_CR18","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00109-007-0246-6","volume":"85","author":"E Diamanti-Kandarakis","year":"2007","unstructured":"Diamanti-Kandarakis E, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med (Berl). 2007;85(12):1413\u201320. https:\/\/doi.org\/10.1007\/s00109-007-0246-6.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"1808_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/bf03401321","volume":"13","author":"E Tantalaki","year":"2014","unstructured":"Tantalaki E, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens). 2014;13(1):65\u201373. https:\/\/doi.org\/10.1007\/bf03401321.","journal-title":"Hormones (Athens)"},{"issue":"1","key":"1808_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Revised","year":"2003","unstructured":"Revised. consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003;19(1):41\u20137. https:\/\/doi.org\/10.1093\/humrep\/deh098.","journal-title":"Hum Reprod"},{"issue":"12","key":"1808_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.clinbiochem.2005.08.008","volume":"38","author":"O Erel","year":"2005","unstructured":"Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103\u201311. https:\/\/doi.org\/10.1016\/j.clinbiochem.2005.08.008.","journal-title":"Clin Biochem"},{"issue":"7","key":"1808_CR22","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.2337\/dc11-0091","volume":"34","author":"J Uribarri","year":"2011","unstructured":"Uribarri J, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011;34(7):1610\u20136. https:\/\/doi.org\/10.2337\/dc11-0091.","journal-title":"Diabetes Care"},{"key":"1808_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340: c332. https:\/\/doi.org\/10.1136\/bmj.c332.","journal-title":"BMJ"},{"key":"1808_CR24","doi-asserted-by":"crossref","unstructured":"Drewnowski A, Almiron-Roig E. Frontiers in Neuroscience Human Perceptions and Preferences for Fat-Rich Foods, in Fat Detection: Taste, Texture, and Post Ingestive Effects, J.P. Montmayeur and J. le Coutre, Editors. 2010, CRC Press\/Taylor & Francis Copyright \u00a9 2010, Taylor & Francis Group, LLC.: Boca Raton (FL), 2009.","DOI":"10.1201\/9781420067767-c11"},{"issue":"6","key":"1808_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13000","volume":"21","author":"JF Tavares","year":"2020","unstructured":"Tavares JF, et al. Can advanced glycation end-products and their receptors be affected by weight loss? A systematic review. Obes Rev. 2020;21(6): e13000. https:\/\/doi.org\/10.1111\/obr.13000.","journal-title":"Obes Rev"},{"issue":"2","key":"1808_CR26","doi-asserted-by":"publisher","first-page":"E226","DOI":"10.1210\/jc.2013-3839","volume":"99","author":"Z Merhi","year":"2014","unstructured":"Merhi Z, et al. Follicular fluid soluble receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve. J Clin Endocrinol Metab. 2014;99(2):E226\u201333. https:\/\/doi.org\/10.1210\/jc.2013-3839.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1808_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1530\/rep-16-0359","volume":"153","author":"B Wang","year":"2017","unstructured":"Wang B, et al. Decreased levels of sRAGE in follicular fluid from patients with PCOS. Reproduction. 2017;153(3):285\u201392. https:\/\/doi.org\/10.1530\/rep-16-0359.","journal-title":"Reproduction"},{"key":"1808_CR28","doi-asserted-by":"crossref","unstructured":"Mouanness M, Merhi Z. Impact of Dietary Advanced Glycation End Products on Female Reproduction: Review of Potential Mechanistic Pathways. Nutrients, 2022. 14(5): p. 966. https:\/\/www.mdpi.com\/2072-6643\/14\/5\/966","DOI":"10.3390\/nu14050966"},{"issue":"11","key":"1808_CR29","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/ijo.2012.107","volume":"36","author":"JM Brix","year":"2012","unstructured":"Brix JM, et al. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity. Int J Obes (Lond). 2012;36(11):1412\u20137. https:\/\/doi.org\/10.1038\/ijo.2012.107.","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"1808_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/sla.0000000000000919","volume":"260","author":"M Parikh","year":"2014","unstructured":"Parikh M, et al. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann Surg. 2014;260(4):617\u201322. https:\/\/doi.org\/10.1097\/sla.0000000000000919. discussion 622\u20134.","journal-title":"Ann Surg"},{"issue":"7","key":"1808_CR31","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.soard.2016.01.016","volume":"12","author":"D Horwitz","year":"2016","unstructured":"Horwitz D, et al. Three-year follow-up comparing metabolic surgery versus medical weight management in patients with type 2 diabetes and BMI 30\u201335. The role of sRAGE biomarker as predictor of satisfactory outcomes. Surg Obes Relat Dis. 2016;12(7):1337\u201341. https:\/\/doi.org\/10.1016\/j.soard.2016.01.016.","journal-title":"Surg Obes Relat Dis"},{"issue":"5","key":"1808_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.diabet.2014.04.008","volume":"40","author":"R Lorenzi","year":"2014","unstructured":"Lorenzi R, et al. Anti-sRAGE autoimmunity in obesity: downturn after bariatric surgery is independent of previous diabetic status. Diabetes Metab. 2014;40(5):356\u201362. https:\/\/doi.org\/10.1016\/j.diabet.2014.04.008.","journal-title":"Diabetes Metab"},{"issue":"2","key":"1808_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.cyto.2015.02.022","volume":"73","author":"I Hagen","year":"2015","unstructured":"Hagen I, et al. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine. 2015;73(2):265\u20139. https:\/\/doi.org\/10.1016\/j.cyto.2015.02.022.","journal-title":"Cytokine"},{"issue":"3","key":"1808_CR34","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1210\/endo.143.3.8691","volume":"143","author":"AL Durlinger","year":"2002","unstructured":"Durlinger AL, et al. Anti-M\u00fcllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002;143(3):1076\u201384. https:\/\/doi.org\/10.1210\/endo.143.3.8691.","journal-title":"Endocrinology"},{"key":"1808_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104535","volume":"90","author":"AL Barbotin","year":"2023","unstructured":"Barbotin AL, et al. Hypothalamic neuroglial plasticity is regulated by anti-M\u00fcllerian hormone and disrupted in polycystic ovary syndrome. EBioMedicine. 2023;90: 104535. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104535.","journal-title":"EBioMedicine"},{"issue":"1","key":"1808_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.fertnstert.2012.11.029","volume":"99","author":"C Tatone","year":"2013","unstructured":"Tatone C, Amicarelli F. The aging ovary\u2013the poor granulosa cells. Fertil Steril. 2013;99(1):12\u20137. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.11.029.","journal-title":"Fertil Steril"},{"issue":"2","key":"1808_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.fertnstert.2012.11.029","volume":"70","author":"JP de Bruin","year":"2004","unstructured":"de Bruin JP, et al. Age-related changes in the ultrastructure of the resting follicle pool in human ovaries. Biol Reprod. 2004;70(2):419\u201324. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.11.029.","journal-title":"Biol Reprod"},{"issue":"3","key":"1808_CR38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/humrep\/deq388","volume":"26","author":"M Jinno","year":"2011","unstructured":"Jinno M, et al. Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology. Hum Reprod. 2011;26(3):604\u201310. https:\/\/doi.org\/10.1093\/humrep\/deq388.","journal-title":"Hum Reprod"},{"issue":"1","key":"1808_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/nu7125524","volume":"14","author":"D Garg","year":"2016","unstructured":"Garg D, Merhi Z. Relationship between Advanced Glycation End Products and Steroidogenesis in PCOS. Reprod Biol Endocrinol. 2016;14(1):71. https:\/\/doi.org\/10.3390\/nu7125524.","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"1808_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/joe-13-0175","volume":"218","author":"A Chatzigeorgiou","year":"2013","unstructured":"Chatzigeorgiou A, et al. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J Endocrinol. 2013;218(3):331\u20137. https:\/\/doi.org\/10.1530\/joe-13-0175.","journal-title":"J Endocrinol"},{"issue":"7","key":"1808_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00394-010-0101-3","volume":"49","author":"PC Chao","year":"2010","unstructured":"Chao PC, et al. Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1\u03b1 and MCP-1 levels in type 2 diabetic patients. Eur J Nutr. 2010;49(7):429\u201334. https:\/\/doi.org\/10.1007\/s00394-010-0101-3.","journal-title":"Eur J Nutr"},{"issue":"11","key":"1808_CR42","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2009-0089","volume":"94","author":"H Vlassara","year":"2009","unstructured":"Vlassara H, et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab. 2009;94(11):4483\u201391. https:\/\/doi.org\/10.1210\/jc.2009-0089.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1808_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jhep.2009.12.007","volume":"52","author":"EL Guimar\u00e3es","year":"2010","unstructured":"Guimar\u00e3es EL, et al. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol. 2010;52(3):389\u201397. https:\/\/doi.org\/10.1016\/j.jhep.2009.12.007.","journal-title":"J Hepatol"},{"issue":"12","key":"1808_CR44","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3109\/09513590.2012.683082","volume":"28","author":"E Deligeoroglou","year":"2012","unstructured":"Deligeoroglou E, et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol. 2012;28(12):974\u20138. https:\/\/doi.org\/10.3109\/09513590.2012.683082.","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"1808_CR45","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40618-020-01351-0","volume":"44","author":"P Moghetti","year":"2021","unstructured":"Moghetti P, Tosi F. Insulin resistance and PCOS: chicken or egg? J Endocrinol Invest. 2021;44(2):233\u201344. https:\/\/doi.org\/10.1007\/s40618-020-01351-0.","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1808_CR46","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3945\/ajcn.115.125427","volume":"103","author":"B de Courten","year":"2016","unstructured":"de Courten B, et al. Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial. Am J Clin Nutr. 2016;103(6):1426\u201333. https:\/\/doi.org\/10.3945\/ajcn.115.125427.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"1808_CR47","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2337\/dc13-0842","volume":"37","author":"AB Mark","year":"2014","unstructured":"Mark AB, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care. 2014;37(1):88\u201395. https:\/\/doi.org\/10.2337\/dc13-0842.","journal-title":"Diabetes Care"},{"issue":"1","key":"1808_CR48","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41598-017-02268-0","volume":"7","author":"E Baye","year":"2017","unstructured":"Baye E, et al. Consumption of diets with low advanced glycation end products improves cardiometabolic parameters: meta-analysis of randomised controlled trials. Sci Rep. 2017;7(1):2266. https:\/\/doi.org\/10.1038\/s41598-017-02268-0.","journal-title":"Sci Rep"},{"issue":"8","key":"1808_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006624","volume":"4","author":"MA Elobeid","year":"2009","unstructured":"Elobeid MA, et al. Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS ONE. 2009;4(8): e6624.","journal-title":"PLoS ONE"},{"issue":"10","key":"1808_CR50","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.jada.2004.07.030","volume":"104","author":"PS Landers","year":"2004","unstructured":"Landers PS, Landers TL. Survival analysis of dropout patterns in dieting clinical trials. J Am Diet Assoc. 2004;104(10):1586\u20138.","journal-title":"J Am Diet Assoc"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-025-01808-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-025-01808-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-025-01808-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:51:16Z","timestamp":1744149076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-025-01808-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1808"],"URL":"https:\/\/doi.org\/10.1007\/s43032-025-01808-8","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The Ministry of Health and the Clinical Research Ethics Boards of Hacettepe University (research ethics project number, KA-21096) approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participant included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All the authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"None of the authors have relevant disclosures or conflicts of interest to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}